Abstract: Several lamivudine-associated HBV resistance mutations, including L180M, A181T, M204I, and M204V, were observed.
Result: Analysis of polymerase gene sequences from baseline and follow-up samples showed the presence of resistance-associated mutations in 5 of these 6 patients, including L180M, A181T, M204I, and M20
Discussion: The current study also detected the M204I variant at baseline in treatment-naive patients, and other mutations such as A181T, L180M, or M204V during follow-up of individuals on a lamivudine-based regimen.
7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Abstract: Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the productio
Method: Plasmids carrying the 1.24-fold HBV genomes of a wild-type genotype Ce strain (HBVWTCe), entecavir-resistant strain carrying L180M/S202G/M204V substitutions (HBVETVR), or adefovir-resistant strain carrying A181T/N236T substitutions (HBVADVR) were constructed for in vitro study as previously described.
Result: We then analyzed the interactions of ETV-TP and CdFA-TP with HBV-RT, in which three amino acid substitutions associated with HBV's resistance to ETV (L180M/S202G/M204V) have been introduced (RTETV-R).
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Result: In fact, M184V in HIV-1 (or M204V in HBV) is not reportedly associated with TDF/TAF resistance.
Result: One possible solution to overcome M184V/I (M204V/I in HBV) resistance is to decrease composition for NRTIs that do not rely on the interactions with Met184.
Result: Previous in vitro antiviral assays have demonstrated that 4'-cyano-containing NRTIs, such as CAdA and CdG, show slightly decreased but moderate activity against HBV with M204V in RT.
Result: The corresponding M204V/I mutation
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Abstract: CONCLUSION: An rtL180M/T184L/A200V/M204V mutant with moderate resistance to TDF monotherapy was selected during sequential nucleoside analogue (NA) treatment in a stepwise manner.
Abstract: In vitro phenotyping demonstrated that the rtL180M/T184L/A200V/M204V mutant had moderate resistance to TDF treatment, with a 4.52-fold higher half maximal effective concentration than that of wild-type virus.
Abstract: METHODS AND RESULTS: Here, we report viral rebound in a patient with chronic hepatitis B who underwent TDF monotherapy and harboured a quadruple mutant consisting of cla
Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Abstract: Three HBV isolates (8.3%) were identified with drug resistance mutations to lamivudine, entericavir, telbivudine and tenofovir, which are amino acid substitutions in the HBV polymerase gene at positions L180M, T184A, M204V.
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.
rt269I Type of Hepatitis B Virus (HBV) Leads to HBV e Antigen Negative Infections and Liver Disease Progression via Mitochondrial Stress Mediated Type I Interferon Production in Chronic Patients With Genotype C Infections.
Introduction: We recently introduced some mutations in the reverse transcriptase (RT) region of Pol related to HCC from genotype C infected patients [rtM80I, rtN139K/T/H, and rtM204I/V].
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Result: No mutations known to cause tenofovir resistance (L180M, A181I/V, A194T, M204V/I, V214A, Q215S, N236T) or lamuvudine (3TC) resistance (L80V/I, I169T, V173L, L180M, A181T, T184S, M204V/I/S, Q215S) were observed.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Result: In case three, multiple mutation patterns were observed from L180M + M204V + I224V + N238H to L180M + M204V + T184S + I224V + N238H under LAM and ADV combined therapy, which developed resistance to ETV.
Result: No single mutation of M204V was detected in both genotypes.
Result: Similarly, samples including mutations of M204V in genotype B and C were 26 and 31, respectively.
Discussion: By contrast, it is selected more frequently than M204V in genotype D.
Discussion: For L-nucleosides resistance, M204I/V
[Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
HBV mutation literature information.
PMID: 
2020
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT